Exploring How Oligonucleotide-Based Immune Modulation Therapies Can Complement Checkpoint Inhibitors And Car-T
26 Jun 2025
New Modalities
- Investigating how oligonucleotide-based therapies can boost immune response and improve checkpoint inhibitor efficacy
- Utilizing oligonucleotides to modulate gene expression, reprogram the tumor microenvironment, and enhance CAR-T cell persistence
- Addressing manufacturing challenges, safety assessments, and regulatory pathways for integrating oligonucleotides into immuno-oncology treatment regimens
Industry Expert
